Alto Neuroscience (ANRO) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for Alto Neuroscience (ANRO).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||
Research And Development | 20M (+69.08%) | 12M (+13.96%) | 11M (-19.74%) | 13M (+31.59%) | 9.97M (-7.69%) | 11M (-17.30%) | 13M (-0.91%) | 13M (+32.46%) | 9.95M (+3.22%) | 9.64M (+20.95%) | 7.97M (+12.73%) | 7.07M (+26.02%) | 5.61M |
Selling General And Administrative | 6.84M (+35.18%) | 5.06M (+14.22%) | 4.43M (-20.32%) | 5.56M (-2.46%) | 5.70M (-8.06%) | 6.20M (+6.35%) | 5.83M (+12.98%) | 5.16M (+16.48%) | 4.43M (+108.96%) | 2.12M (+21.14%) | 1.75M (-14.63%) | 2.05M (+28.93%) | 1.59M |
Operating Expenses | 27M (+59.09%) | 17M (+14.11%) | 15M (-19.97%) | 19M (+19.13%) | 16M (-7.76%) | 17M (-10.01%) | 19M (+3.00%) | 18M (+27.45%) | 14M (+22.26%) | 12M (+21.09%) | 9.72M (+6.46%) | 9.13M (+26.81%) | 7.20M |
Depreciation And Amortization | 180K (-5.26%) | 190K (-5.00%) | 200K (+100.00%) | 100K (-41.18%) | 170K (+54.55%) | 110K (-45.00%) | 200K (+100.00%) | 100K (0.00%) | 100K (+11.11%) | 90K (-10.00%) | 100K (0.00%) | 100K (+11.11%) | 90K |
Operating Income | |||||||||||||
Operating Income | -27.14M (+59.18%) | -17.05M (+14.05%) | -14.95M (-19.97%) | -18.68M (+19.13%) | -15.68M (-7.76%) | -17.00M (-10.01%) | -18.89M (+3.00%) | -18.34M (+27.45%) | -14.39M (+22.36%) | -11.76M (+20.99%) | -9.72M (+6.58%) | -9.12M (+26.67%) | -7.20M |
Ebit | -27.14M (+59.18%) | -17.05M (+14.05%) | -14.95M (-19.97%) | -18.68M (+19.13%) | -15.68M (-7.76%) | -17.00M (-10.01%) | -18.89M (+3.00%) | -18.34M (+27.45%) | -14.39M (+22.36%) | -11.76M (+20.99%) | -9.72M (+6.58%) | -9.12M (+26.67%) | -7.20M |
EBITDA | -26.95M (+59.85%) | -16.86M (+14.31%) | -14.75M (-20.61%) | -18.58M (+19.87%) | -15.50M (-8.23%) | -16.89M (-9.63%) | -18.69M (+2.47%) | -18.24M (+27.64%) | -14.29M (+22.35%) | -11.68M (+21.41%) | -9.62M (+6.65%) | -9.02M (+26.86%) | -7.11M |
Other Income / Expenses | |||||||||||||
Interest Income | 1.56M (0.00%) | 1.56M (+1.96%) | 1.53M (-8.93%) | 1.68M (-8.20%) | 1.83M (-14.08%) | 2.13M (-14.80%) | 2.50M (-6.02%) | 2.66M (+70.51%) | 1.56M (+110.81%) | 740K (+4.23%) | 710K (+5.97%) | 670K (+191.30%) | 230K |
Interest Expense | 550K (-3.51%) | 570K (-12.31%) | 650K (0.00%) | 650K (+8.33%) | 600K (+81.82%) | 330K (-5.71%) | 350K (0.00%) | 350K (0.00%) | 350K (-2.78%) | 360K (0.00%) | 360K (+9.09%) | 330K (+3.13%) | 320K |
Net Interest Income | 1.56M (0.00%) | 1.56M (+1.96%) | 1.53M (-8.93%) | 1.68M (-8.20%) | 1.83M (-14.08%) | 2.13M (-14.80%) | 2.50M (-6.02%) | 2.66M (+70.51%) | 1.56M (+110.81%) | 740K (+4.23%) | 710K (+5.97%) | 670K (+191.30%) | 230K |
Other Non Operating Income | 900K (-71.25%) | 3.13M (+306.49%) | 770K (-21.43%) | 980K (+92.16%) | 510K (-92.90%) | 7.18M (+241.90%) | 2.10M (-9.09%) | 2.31M (+138.14%) | 970K (-35.33%) | 1.50M (+158.62%) | 580K (+26.09%) | 460K | -80.00K |
Net Income | |||||||||||||
Net Income From Continuing Operations | -26.24M (+62.18%) | -16.18M (+14.10%) | -14.18M (-19.93%) | -17.71M (+16.74%) | -15.17M (-0.20%) | -15.20M (-9.42%) | -16.78M (+4.68%) | -16.03M (+19.45%) | -13.42M (+19.61%) | -11.22M (+22.76%) | -9.14M (+5.54%) | -8.66M (+18.96%) | -7.28M |
Net Income | -26.24M (+62.18%) | -16.18M (+14.10%) | -14.18M (-19.93%) | -17.71M (+16.74%) | -15.17M (-0.20%) | -15.20M (-9.42%) | -16.78M (+4.68%) | -16.03M (+19.45%) | -13.42M (+19.61%) | -11.22M (+22.76%) | -9.14M (+5.54%) | -8.66M (+18.96%) | -7.28M |